MADISON, Wis. _ Exact Sciences Corp. (EXAS) on Wednesday reported a loss of $36.4 million in its second quarter. On a per-share basis, the Madison, Wisconsin-based company said it had a loss of 30 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 33 cents per share. The molecular diagnostics company posted revenue of $102.9 million in the period, which fell short of Street forecasts. Five analysts surveyed by Zacks expected $105.4 million. Exact Sciences expects full-year revenue in the range of $420 million to $430 million. Exact Sciences shares have increased 13 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $59.12, an increase of 56 percent in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EXAS at … [Read more...] about Exact Sciences: 2Q Earnings Snapshot
Published May 30, 2018 Markets Motley Fool Facebook Twitter Comments Print The stock market rebounded sharply on Wednesday, and major benchmarks recovered most of the ground they lost on Tuesday, posting gains of around 1%. Concerns about financial difficulties in the Italian economy seemed to ebb in investors' minds, as those looking more closely at the problem came to the conclusion that U.S. exposure to any troubles the European Union might face as a result of pressure on its common currency wouldn't be as large as initially feared. In addition, some good news from several parts of the market improved overall sentiment. Movado Group (NYSE: MOV), Fiat Chrysler Automobiles (NYSE: FCAU), and Exact Sciences (NASDAQ: EXAS) were among the best performers on the day. Here's why they did so well. Movado gets moving Continue Reading Below Shares of Movado Group soared nearly 17% after the watchmaker announced its fiscal first-quarter financial results. The … [Read more...] about Why Movado Group, Fiat Chrysler Automobiles, and Exact Sciences Jumped Today
Exact Sciences Corp. is spending more than $300 million to expand its facilities in the Madison area, the company disclosed in documents filed with federal regulators.The filing on Thursday is believed to be the first time Exact Sciences has publicly tallied the extent of its series of construction projects intended to help the company keep up with growing demand for its Cologuard home test kit for colorectal cancer and to develop future cancer testing products.The Madison company is putting an addition onto its Cologuard processing lab on Badger Road and is building a new lab, offices and parking at the former site of Spectrum Brands headquarters, just off Schroeder Road.It also is expanding facilities at two of the three buildings the company occupies in University Research Park, spokesman J.P. Fielder said.Those projects — including construction, equipment and technology — translate into $50.9 million in contracts underway as of March 31 and another $256.8 million … [Read more...] about Exact Sciences’ construction projects top $300 million
Published April 08, 2018 Markets Motley Fool Facebook Twitter Comments Print There's no doubt that Exact Sciences (NASDAQ: EXAS) is a battleground stock. Bulls have long believed that the company's innovative Cologuard colon cancer detection test would convince millions of patients to be step up and get screened. Bears have pointed out that Exact has burned through massive amounts of capital in its history, and note that its test wasn't compelling enough to convince providers and insurers to jump on board and cover it. Based on the stock's performance over the last few years, the bulls have been fully vindicated thus far. Exact Sciences' share price has quadrupled over the last five years as demand for Cologuard has been off-the-charts strong. Does that mean that it is too late for new investors to get on board? Continue Reading Below An innovative solution to a deadly problem Colon cancer is expected to cause more than 50,000 deaths in the U.S. in 2018, … [Read more...] about Is Exact Sciences Corp. Still a Buy in 2018?
Exact Sciences Corp. is adding an executive of Abbott Laboratories/AbbVie, one of the biggest U.S. pharmaceutical companies, to lead its Cologuard campaign.Exact created the position of president, Cologuard, for Mark Stenhouse; he will join Exact’s Madison headquarters on April 2.Stenhouse is vice president, U.S. Immunology at AbbVie. He leads sales and marketing for Humira, an anti-inflammatory drug for psoriasis and rheumatoid arthritis. It has been the top-selling drug in the U.S. for the past five years. AbbVie, of North Chicago, Illinois, reported $28.2 billion in revenue last year and said Humira sales made up $18.4 billion of that.Cologuard, a DNA stool test for colorectal cancer, is Exact’s only product on the market right now. But the company is working with Mayo Clinic researchers on several other tests to screen for different types of cancer.“The story of Exact Sciences and the science powering Cologuard are incredibly compelling, which is why I’m … [Read more...] about Exact Sciences lures leader of AbbVie’s top-selling Humira sales team